Lv4
460 积分 2022-06-30 加入
First-line benmelstobart plus anlotinib versus sunitinib in advanced renal cell carcinoma (ETER100): a multicentre, randomised, open-label, phase 3 trial
4天前
已完结
Fruquintinib Plus Sintilimab in Patients with Treatment-Naive and Previously Treated Advanced Renal Cell Carcinoma: Results from a Phase Ib/II Clinical Trial
4天前
已完结
Sintilimab Plus Axitinib for Advanced Fumarate Hydratase–Deficient Renal Cell Carcinoma
4天前
已完结
Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial
1个月前
已完结
Therapeutic sequencing in advanced renal cell carcinoma: How to choose considering clinical and biological factors
1个月前
已完结
Safety and Efficacy of Second-Line TKI Plus Anti-PD1 in Metastatic Non-Clear Cell Renal Cell Carcinoma: A Real-World Study
1个月前
已完结
Efficacy of Treatments After Lenvatinib in Patients with Advanced Renal Cell Carcinoma
1个月前
已完结
Sintilimab Plus Axitinib for Advanced Fumarate Hydratase–Deficient Renal Cell Carcinoma
1个月前
已完结
Effectiveness and Safety of Cabozantinib Treatment in Patients with Advanced Renal Cell Carcinoma in Spanish and Portuguese Real-world Practice: The SOGUG-SPRWEC Study
1个月前
已完结
Management of Advanced Renal Cell Carcinoma
1个月前
已关闭
皖公网安备34019202002308
